$7.85
+0.3
(+3.97%)▲
4.2%
Downside
Day's Volatility :4.33%
Upside
0.13%
48.66%
Downside
52 Weeks Volatility :49.31%
Upside
1.26%
Period | Biocryst Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 81.49% | 6.5% | 0.0% |
6 Months | 38.79% | 7.1% | 0.0% |
1 Year | -4.67% | 9.8% | 0.0% |
3 Years | -56.23% | 14.2% | -20.2% |
Market Capitalization | 1.6B |
Book Value | - $2.31 |
Earnings Per Share (EPS) | -1.07 |
PEG Ratio | -0.28 |
Wall Street Target Price | 14.0 |
Profit Margin | -58.69% |
Operating Margin TTM | -15.62% |
Return On Assets TTM | -10.85% |
Return On Equity TTM | -1925.37% |
Revenue TTM | 355.4M |
Revenue Per Share TTM | 1.81 |
Quarterly Revenue Growth YOY | 34.9% |
Gross Profit TTM | 10.9M |
EBITDA | -82.1M |
Diluted Eps TTM | -1.07 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.61 |
EPS Estimate Next Year | -0.36 |
EPS Estimate Current Quarter | -0.21 |
EPS Estimate Next Quarter | -0.16 |
What analysts predicted
Upside of 78.34%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 20.7M | ↓ 18.0% |
Net Income | -101.3M | ↑ 53.92% |
Net Profit Margin | -490.25% | ↓ 229.07% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 48.8M | ↑ 136.45% |
Net Income | -120.1M | ↑ 18.58% |
Net Profit Margin | -245.86% | ↑ 244.39% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 17.8M | ↓ 63.53% |
Net Income | -196.6M | ↑ 63.72% |
Net Profit Margin | -1.1K% | ↓ 857.71% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 157.2M | ↑ 782.38% |
Net Income | -184.1M | ↓ 6.36% |
Net Profit Margin | -117.11% | ↑ 986.46% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 270.8M | ↑ 72.31% |
Net Income | -247.1M | ↑ 34.26% |
Net Profit Margin | -91.25% | ↑ 25.86% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 331.4M | ↑ 22.37% |
Net Income | -226.5M | ↓ 8.33% |
Net Profit Margin | -68.36% | ↑ 22.89% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 79.5M | ↑ 4.9% |
Net Income | -71.5M | ↑ 68.25% |
Net Profit Margin | -89.94% | ↓ 33.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 68.8M | ↓ 13.54% |
Net Income | -53.3M | ↓ 25.45% |
Net Profit Margin | -77.54% | ↑ 12.4% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 82.5M | ↑ 19.94% |
Net Income | -75.3M | ↑ 41.24% |
Net Profit Margin | -91.31% | ↓ 13.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 86.7M | ↑ 5.15% |
Net Income | -36.1M | ↓ 52.01% |
Net Profit Margin | -41.67% | ↑ 49.64% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 93.4M | ↑ 7.68% |
Net Income | -61.7M | ↑ 70.77% |
Net Profit Margin | -66.09% | ↓ 24.42% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 92.8M | ↓ 0.69% |
Net Income | -35.4M | ↓ 42.69% |
Net Profit Margin | -38.14% | ↑ 27.95% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 146.8M | ↓ 17.62% |
Total Liabilities | 97.6M | ↑ 3.3% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 175.3M | ↑ 19.37% |
Total Liabilities | 137.0M | ↑ 40.39% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 334.7M | ↑ 90.96% |
Total Liabilities | 354.0M | ↑ 158.32% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 588.2M | ↑ 75.72% |
Total Liabilities | 695.1M | ↑ 96.38% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 550.0M | ↓ 6.49% |
Total Liabilities | 844.6M | ↑ 21.5% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 517.0M | ↓ 6.01% |
Total Liabilities | 972.5M | ↑ 15.14% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 550.0M | ↓ 1.54% |
Total Liabilities | 844.6M | ↑ 5.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 509.7M | ↓ 7.32% |
Total Liabilities | 838.0M | ↓ 0.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 529.9M | ↑ 3.95% |
Total Liabilities | 918.6M | ↑ 9.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | -685.5M | ↓ 229.37% |
Total Liabilities | 933.9M | ↑ 1.67% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 517.0M | ↓ 175.41% |
Total Liabilities | 972.5M | ↑ 4.13% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 467.9M | ↓ 9.49% |
Total Liabilities | 944.1M | ↓ 2.92% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -92.6M | ↑ 124.98% |
Investing Cash Flow | 4.8M | ↓ 107.18% |
Financing Cash Flow | 62.5M | ↓ 53.94% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -89.6M | ↓ 3.22% |
Investing Cash Flow | 77.9M | ↑ 1534.52% |
Financing Cash Flow | 99.1M | ↑ 58.55% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -137.2M | ↑ 53.17% |
Investing Cash Flow | -6.9M | ↓ 108.8% |
Financing Cash Flow | 302.7M | ↑ 205.45% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -142.2M | ↑ 3.6% |
Investing Cash Flow | 15.8M | ↓ 330.51% |
Financing Cash Flow | 359.7M | ↑ 18.82% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -161.9M | ↑ 13.85% |
Investing Cash Flow | -128.2M | ↓ 911.43% |
Financing Cash Flow | 88.0M | ↓ 75.53% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -23.8M | ↓ 26.49% |
Investing Cash Flow | 77.2M | ↓ 211.03% |
Financing Cash Flow | 4.2M | ↓ 94.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -47.5M | ↑ 99.22% |
Investing Cash Flow | -107.1M | ↓ 238.72% |
Financing Cash Flow | 5.1M | ↑ 20.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.8M | ↓ 60.4% |
Investing Cash Flow | -19.0M | ↓ 82.23% |
Financing Cash Flow | 29.4M | ↑ 478.22% |
Sell
Neutral
Buy
Biocryst Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Biocryst Pharmaceuticals Inc | 22.17% | 38.79% | -4.67% | -56.23% | 133.75% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Biocryst Pharmaceuticals Inc | NA | NA | -0.28 | -0.61 | -19.25 | -0.11 | NA | -2.31 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Biocryst Pharmaceuticals Inc | Buy | $1.6B | 133.75% | NA | -58.69% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Biocryst Pharmaceuticals Inc
Revenue is down for the last 2 quarters, 93.40M → 92.76M (in $), with an average decrease of 0.7% per quarter
Netprofit is up for the last 2 quarters, -61.73M → -35.37M (in $), with an average increase of 74.5% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 66.3%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 242.7%
BlackRock Inc
Vanguard Group Inc
State Street Corporation
venBio Select Advisor LLC
Baker Bros Advisors LP
Kynam Capital Management, LP
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Organization | Biocryst Pharmaceuticals Inc |
Employees | 536 |
CEO | Mr. Jon P. Stonehouse |
Industry | Health Technology |
A Spac I Acquisition Corp
$7.85
+3.97%
Keyarch Acquisition Corp
$7.85
+3.97%
Connexa Sports Technologies Inc
$7.85
+3.97%
Us Value Etf
$7.85
+3.97%
First Wave Biopharma Inc
$7.85
+3.97%
Global X Msci Next Emerging
$7.85
+3.97%
Fat Projects Acquisition Corp
$7.85
+3.97%
Capital Link Global Fintech
$7.85
+3.97%
Applied Uv Inc
$7.85
+3.97%